204 related articles for article (PubMed ID: 20186046)
1. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
O'Connor SM; Beriwal S; Dabbs DJ; Bhargava R
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):268-72. PubMed ID: 20186046
[TBL] [Abstract][Full Text] [Related]
2. Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
Kraus JA; Dabbs DJ; Beriwal S; Bhargava R
Mod Pathol; 2012 Jun; 25(6):869-76. PubMed ID: 22301704
[TBL] [Abstract][Full Text] [Related]
3. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score.
Chaudhary LN; Jawa Z; Szabo A; Visotcky A; Chitambar CR
Hematol Oncol Stem Cell Ther; 2016 Jun; 9(2):48-54. PubMed ID: 26808222
[TBL] [Abstract][Full Text] [Related]
4. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Badve SS; Baehner FL; Gray RP; Childs BH; Maddala T; Liu ML; Rowley SC; Shak S; Perez EA; Shulman LJ; Martino S; Davidson NE; Sledge GW; Goldstein LJ; Sparano JA
J Clin Oncol; 2008 May; 26(15):2473-81. PubMed ID: 18487567
[TBL] [Abstract][Full Text] [Related]
5. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
6. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
8. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
Park MM; Ebel JJ; Zhao W; Zynger DL
Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
10. Oncotype DX RT-qPCR assay for ER and PR correlation with IHC: a study of 3 different clones.
Khoury T; Yan L; Liu S; Bshara W
Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):178-87. PubMed ID: 24992175
[TBL] [Abstract][Full Text] [Related]
11. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.
Clark BZ; Dabbs DJ; Cooper KL; Bhargava R
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):287-91. PubMed ID: 23060300
[TBL] [Abstract][Full Text] [Related]
12. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
[TBL] [Abstract][Full Text] [Related]
14. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
15. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.
Dvorak L; Dolan M; Fink J; Varghese L; Henriksen J; Gulbahce HE
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):196-9. PubMed ID: 22914611
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemistry assays and real-time reverse transcription-polymerase chain reaction for analyzing hormone receptor status in human breast carcinoma.
Oda M; Arihiro K; Kataoka T; Osaki A; Asahara T; Ohdan H
Pathol Int; 2010 Apr; 60(4):305-15. PubMed ID: 20403033
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
19. Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT
Schildgen V; Warm M; Brockmann M; Schildgen O
Sci Rep; 2019 Dec; 9(1):20266. PubMed ID: 31889145
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
